Oxycodone Depot Lannacher (Oxycodone Hydrochloride)

Oxycodone Hydrochloride, the active ingredient in Oxycodone Depot Lannacher, is an opioid analgesic presented as a depot formulation for oral use. It is employed in the management of moderate to severe pain, particularly when continuous long‑term analgesia is required, and is suitable for adult patients.

GNH USA supplies Oxycodone Depot Lannacher as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxycodone Depot Lannacher is an opioid analgesic that acts on the central nervous system to control pain. - Chronic cancer‑related pain: provides sustained relief over several days, reducing the need for frequent dosing. - Post‑operative pain after major surgery: maintains steady analgesia during the critical recovery period. - Severe non‑cancer chronic pain: offers continuous opioid coverage when other regimens are insufficient.

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea and vomiting: stimulation of the chemoreceptor trigger zone. - Drowsiness or sedation: central nervous system depression. - Dry mouth: decreased salivary secretion. - Dizziness: orthostatic hypotension or vestibular effects. - Pruritus: histamine release at the skin.

Serious or Rare Side Effects: - Respiratory depression: reduced response to carbon dioxide. - Severe hypotension: profound vasodilation. - Opioid use disorder: dependence and addiction potential. - Adrenal insufficiency: suppression of the hypothalamic‑pituitary‑adrenal axis. - Seizures: lowered seizure threshold in susceptible individuals. - Anaphylaxis: acute Ig‑mediated hypersensitivity reaction.

When prescribing Oxycodone Depot Lannacher, clinicians should consider several safety aspects. - Assess pain severity and opioid tolerance: ensure the patient requires long‑acting opioid therapy. - Evaluate respiratory function: patients with compromised breathing are at higher risk of depression. - Review concomitant CNS depressants: avoid additive sedation or respiratory effects. - Monitor for signs of dependence: assess for misuse or addiction behaviors. - Adjust for renal or hepatic impairment: dose may need modification based on organ function. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Oxycodone Depot Lannacher can interact with a range of medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines or other sedative‑hypnotics: combined use can cause profound respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase oxycodone plasma concentrations. - Opioid antagonists (e.g., naloxone): can precipitate acute withdrawal.

Moderate Interactions (Monitor Closely): - CNS depressants such as antihistamines or muscle relaxants: may enhance sedation. - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): can reduce conversion to active metabolites. - Diuretics: may potentiate hypotensive effects. - Alcohol: additive central nervous system depression. - Serotonergic agents: risk of serotonin syndrome when combined with opioids.